

VistA Blood Establishment Computer Software (VBECS) 2.3.2 Rev D

Release Notes Version 1.0

Department of Veterans Affairs

Enterprise Project Management Office

This page intentionally left blank.

# Revision History

| **Date** | **Revision** | **Description** | **Author** |
| --- | --- | --- | --- |
| 04/17/20 | 1.0 | VBECS 2.3.2 Rev D  Initial version (Task 1250684) | BBM Team |

This page intentionally left blank.

Table of Contents

[Revision History i](#_Toc37923098)

[Introduction 1](#_Toc37923099)

[Changed Features and Functions 1](#_Toc37923100)

[Untestable System-Level Corrected Code Requests 1](#_Toc37923101)

[VistA Software Dependencies 1](#_Toc37923102)

[VBECS User Documents 2](#_Toc37923103)

[Customer Support 4](#_Toc37923104)

[Problems? 4](#_Toc37923105)

[References 4](#_Toc37923106)

[VBECS SharePoint Site 4](#_Toc37923107)

[Installation Qualification (IQ) Documentation 4](#_Toc37923108)

[Validation Planning 6](#_Toc37923109)

[Table 1: Updates by Option 7](#_Toc37923110)

[Table 2: New Blood Products for COVID-19 Treatment 8](#_Toc37923111)

[Table 3: Possible Modifications for Newly Added Products 10](#_Toc37923112)

This page intentionally left blank.

# Introduction

*VistA Blood Establishment Computer Software (VBECS) 2.3.2 Rev D Release Notes* contains information for changes and corrections made to VBECS in the 2.3.2 Rev D patch.

Perform a local evaluation and risk assessment of the changes to determine the requirements for local validation of the changes, including documentation of the assessment activities. See Validation Planning.

# Changed Features and Functions

This revision letter patch release is centrally focused around providing additional blood product updates released from International Council for Commonality in Blood Banking Automation, Inc. (ICCBBA) for the treatment of COVID-19. Blood products contained in ICCBBA releases 7.35.2, 7.35.3 and 7.35.4 are included. In addition, the text for the donation types of 2, L, E, and 3 is being updated to indicate directed recipient rather than directed donor.

Table 1: Updates by Option provides complete lists of included changes.

For a full list of new product codes see tables 2 and 3.

## Untestable System-Level Corrected Code Requests

* None

## VistA Software Dependencies

* No VistA patch is required for this blood product-only release.

## VBECS User Documents

The following is a list of all the VBECS user documents that apply to the VBECS 2.3.2 Rev D patch release. The **Updated** column identifies the documents that have been updated with this VBECS 2.3.2 Rev D revision letter patch release.

These user documents are available from the VA Software Document Library (VDL) at <https://www.va.gov/vdl/application.asp?appid=182>.

|  |  |  |
| --- | --- | --- |
| **User Document** | **Version** | **Updated** |
| *VistA Blood Establishment Computer Software (VBECS) 2.3.2 User Guide* | 4.0 | No |
| *VistA Blood Establishment Computer Software (VBECS) 2.3.2 Administrator User Guide* | 3.0 | No |
| *VistA Blood Establishment Computer Software (VBECS) 2.3.2 Known Defects and Anomalies* | 3.0 | No |
| *VistA Blood Establishment Computer Software (VBECS) 2.3.2 Technical Manual-Security Guide* | 1.0 | No |
| *VistA Blood Establishment Computer Software (VBECS) - Echo Interface Configuration and Setup Guide* | 5.0 | No |
| *VistA Blood Establishment Computer Software (VBECS) - Erytra Interface Configuration and Setup Guide* | 2.0 | No |
| *VistA Blood Establishment Computer Software (VBECS) - ProVue Interface Configuration and Setup Guide* | 5.0 | No |
| *VistA Blood Establishment Computer Software (VBECS) - Vision Interface Configuration and Setup Guide* | 4.0 | No |

The following is a list of all the VBECS FAQ documents that apply to the VBECS 2.3.2 Rev D patch release. The **Updated** column identifies the documents that have been updated with this VBECS 2.3.2 Rev D revision letter patch release.

These FAQ documents are available from the VA SharePoint site at REDACTED

|  |  |  |
| --- | --- | --- |
| **FAQ Document** | **Version** | **Updated** |
| *FAQ ABO subgroup Interpretations* | 11/22/16 | No |
| *FAQ Ancillary VistA Validation* | 11/28/17 | No |
| *FAQ Antibodies with No Antigen Negative Requirement* | 10/15/14 | No |
| *FAQ Blood Product Table Processes* | 03/28/19 | No |
| *FAQ CAP Comprehensive Transfusions Medicine Crossmatch Survey* | 11/22/16 | No |
| *FAQ Compound Antibodies* | 02/27/13 | No |
| *FAQ CPRS VBECS Order Details* | 04/01/09 | No |
| *FAQ Database Conversion Oddballs* | 09/15/09 | No |
| *FAQ Documenting Unhandled Exceptions* | 05/21/07 | No |
| *FAQ Handling ABO Incompatible Transfusion Situations* | 09/23/14 | No |
| *FAQ How to File a New Service Request for Changes to VBECS* | 12/08/16 | No |
| *FAQ How to take faster screen shots from Remote Desktop Session* | 12/17/14 | No |
| *FAQ Identifying a Comparable Blood Product Code* | 03/28/19 | No |
| *FAQ Local Facilities* | 12/27/19 | No |
| *FAQ Modification Target Not Available* | 11/28/17 | No |
| *FAQ Multidivisional QC Rack Workaround* | 11/28/17 | No |
| *FAQ Order Status Clarification* | 11/15/17 | No |
| *FAQ Polyspecific AHG Not Used for Testing* | 01/29/10 | No |
| *FAQ Proper Use of PIV Card with VBECS* | 11/04/19 | No |
| *FAQ QC Setup* | 01/29/10 | No |
| *FAQ Retesting QC* | 11/01/11 | No |
| *FAQ Retrieving an Expired Order* | 12/07/17 | No |
| *FAQ The Difference Between Transfusion Only and Full Service Facility Types* | 02/08/10 | No |
| *FAQ VBECS Blood Product Hierarchy* | 03/28/19 | No |
| *FAQ VBECS Computer Crossmatch Decision Tree* | 02/08/12 | No |
| *FAQ Weak D Policy* | 01/11/10 | No |

# Customer Support

## Problems?

Contact your Local Office of Information Technology (OIT) or Laboratory Information Manager (LIM) if you encounter VistA or CPRS connection problems and for training support **before** contacting the Service Desk (SD).

|  |
| --- |
| * Please ensure local contact information is available at all times. SD support will engage Enterprise Operations (EO) personnel as needed. * Problems with connectivity to VistA and CPRS may require personnel from EO with VBECS server administrator access and VistA IT support access. * If you experience a Food and Drug Administratin (FDA) reportable adverse event (patient death or serious injury) that VBECS may have caused or contributed to, contact the Service Desk directly to enter a ticket for Blood Bank software support. |

If the problem remains unresolved after local VistA triage, call the Service Desk (below) and specify the Enterprise Application be set as VistA Blood Establishment Computer Software. This will cause the Assignment group to default to NTL Alert Blood Bank & VBECS, which alerts the Clin2 team.

**Service Desk Contact**

## REDACTEDReferences

* *ISBT128 Standard Technical Specification v 5.10.0*

|  |
| --- |
| * *Blood Product Revisions ICCBBA Version 7.35.4, April 15th 2020* |

## VBECS SharePoint Site

The VBECS SharePoint site provides a location for additional information related to the VBECS application such as FAQs, installation status, and release history.

REDACTED.

# Installation Qualification (IQ) Documentation

The expedited patch installation process will continue with the installation of VBECS 2.3.2 Rev D.

|  |  |
| --- | --- |
| **Test Account Upgrade to VBECS 2.3.2 Revision D** | |
| Required Patch Installation | VistA Patch: N/A  Server Patch: VBECS 2.3.2 Revision D |
| Installation Process for VBECS 2.3.2 Rev D | Installed by the BBM team, all sites will be installed in one day. The date of installation will be communicated through a ListServ announcement. |
| Expected Downtime | None |
| Installation Communication for VBECS 2.3.2 Rev D | The planned completion time for all test installs will be provided on the VBECS SharePoint site. |
| Site Responsibility | * Join VBECS-L message board on ListServ, if needed. * Please communicate any changes to your site supervisor and Point of Contact (POC) since the last patch install to the BBM team to the email group “VA OIT BBM Team”. |
| Site Record of Patch Installation | Sites should take and save a screenshot of the VBECS Help, About window after the Test installation is performed. This displays the VBECS updated version information. |

|  |  |
| --- | --- |
| **Production Account Upgrade to VBECS 2.3.2 Revision D** | |
| Required Patch Installation | VistA Patch: N/A  Server Patch: VBECS 2.3.2 Revision D |
| Installation Process for VBECS 2.3.2 Rev D | Installed by the BBM team, all sites will be installed in one day. The date of installation will be communicated through a ListServ announcement. |
| Expected Downtime | You will be able to use VBECS during the patch installation. VBECS installation on your production account only lasts a few minutes and is invisible to users.  If you encounter any disruption or errors while viewing or printing reports during the installation, try again after a few minutes. |
| Installation Communication for VBECS 2.3.2 Rev D | The status of production installs will be provided on the VBECS SharePoint site. |
| Site Responsibility | * Perform local validation, training, and set-up requirements prior to Production installation. * Join VBECS-L message board on ListServ, if needed. * Please communicate any changes to your site supervisor and Point of Contact (POC) since the last patch install to the BBM team to the email group “VA OIT BBM Team”. |
| Site Record of Patch Installation | Sites should take and save a screenshot of the VBECS Help, About window after Production installation is performed. This displays the VBECS updated version information. |

# Validation Planning

The following is a flowchart to help assess changes for validation planning.



# Table 1: Updates by Option

| ID | Option | **Problem Summary** | **Change Summary** | **Validation Scenario** | **Change applies to my facility. (Y/N)** | **Local risk Assessment**  **(Low, Med, High)** | **SOP revision required. If yes, identify it.** | **Staff training needed.**  **(Y/N)** | **Scenarios or validation must be performed.**  **(Y/N)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | Blood Products  1250187 | Update blood product table with new ICCBBA blood product codes from version 7.35.2 through 7.35.4 with a primary focus on the convalescent plasma products used for treatment of COVID-19. | New blood products were added to VBECS.  For a full list of new product codes for COVID-19 treatment, see **Table 2**.  For possible modifications for new blood products see **Table 3**. | Validate only blood products that you may receive from your supplier. Use Tools, Blood Products to associate the blood products with an active facility. |  |  |  |  |  |
| 2 | Donation Types  1253119 | Update text of the following donation types to indicate directed recipient rather than directed donor:  **2 - "For Directed Donor Use Only"**  **L - "For Directed Donor Use Only, Limited Exposure"**  **E - "For Directed Donor Use Only, Medical Exception"**  **3 - "For Directed Donor Use Only, Biohazardous"** | New text of donation types:  **2 - "For Directed Recipient Use Only"**  **L - "For Directed Recipient Use Only, Limited Exposure"**  **E - "Medical Exception, for Specified Recipient Only"**  **3 - "For Directed Recipient Use Only, Biohazardous"** | No validation required. |  |  |  |  |  |

# Table 2: New Blood Products for COVID-19 Treatment

| **Component** | **Product Code** | **Modifiable** | **Product Type** | **Long Name** | **Short Name** | **Maximum Storage Hours** |
| --- | --- | --- | --- | --- | --- | --- |
| FRESH FROZEN PLASMA | E9784 | Yes | Apheresis CONVALESCENT PLASMA | Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|1st container|Psoralen-treated|COVID-19 | PLASMA AFR Conv ACD-A 1C Psoraln COVID-19 | 8760 |
| FRESH FROZEN PLASMA | E9785 | Yes | Apheresis CONVALESCENT PLASMA | Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|2nd container|Psoralen-treated|COVID-19 | PLASMA AFR Conv ACD-A 2C Psoraln COVID-19 | 8760 |
| FRESH FROZEN PLASMA | E9786 | Yes | Apheresis CONVALESCENT PLASMA | Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|3rd container|Psoralen-treated|COVID-19 | PLASMA AFR Conv ACD-A 3C Psoraln COVID-19 | 8760 |
| FRESH FROZEN PLASMA | E9787 | Yes | Apheresis CONVALESCENT PLASMA | Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|4th container|Psoralen-treated|COVID-19 | PLASMA AFR Conv ACD-A 4C Psoraln COVID-19 | 8760 |
| FRESH FROZEN PLASMA | E9788 | Yes | Thawed Apheresis CONVALESCENT PLASMA | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Psoralen-treated|COVID-19 | PLASMA Conv AFR Thaw ACD-A Psoraln COVID-19 | 120 |
| FRESH FROZEN PLASMA | E9789 | Yes | Thawed Apheresis CONVALESCENT PLASMA | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|1st container|Psoralen-treated|COVID-19 | PLASMA Conv AFR Thaw ACD-A 1C Psoraln COVID-19 | 120 |
| FRESH FROZEN PLASMA | E9790 | Yes | Thawed Apheresis CONVALESCENT PLASMA | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|2nd container|Psoralen-treated|COVID-19 | PLASMA Conv AFR Thaw ACD-A 2C Psoraln COVID-19 | 120 |
| FRESH FROZEN PLASMA | E9791 | Yes | Thawed Apheresis CONVALESCENT PLASMA | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|3rd container|Psoralen-treated|COVID-19 | PLASMA Conv AFR Thaw ACD-A 3C Psoraln COVID-19 | 120 |
| FRESH FROZEN PLASMA | E9792 | Yes | Thawed Apheresis CONVALESCENT PLASMA | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|4th container|Psoralen-treated|COVID-19 | PLASMA Conv AFR Thaw ACD-A 4C Psoraln COVID-19 | 120 |
| FRESH FROZEN PLASMA | E9793 | Yes | Thawed Apheresis CONVALESCENT PLASMA | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Irradiated|COVID-19 | PLASMA Conv AFR Thaw ACD-A IRD COVID-19 | 120 |
| FRESH FROZEN PLASMA | E9794 | Yes | CONVALESCENT PLASMA | CONVALESCENT PLASMA|CPD/XX/<=-25C|COVID-19 | PLASMA Conv CPD COVID-19 | 8760 |
| FRESH FROZEN PLASMA | E9795 | Yes | Apheresis CONVALESCENT PLASMA | Apheresis CONVALESCENT PLASMA|NaCitrate/XX/<=-25C|COVID-19 | PLASMA AFR Conv NaCit COVID-19 | 8760 |
| FRESH FROZEN PLASMA | E9796 | Yes | Liquid CONVALESCENT PLASMA | Liquid CONVALESCENT PLASMA|NS/XX/refg|Irradiated|COVID-19 | PLASMA Conv Liq NS IRD COVID-19 | 624 |
| FRESH FROZEN PLASMA | E9797 | Yes | Liquid Apheresis CONVALESCENT PLASMA | Liquid Apheresis CONVALESCENT PLASMA|NS/XX/refg|Irradiated|COVID-19 | PLASMA Conv AFR Liq NS IRD COVID-19 | 120 |
| FRESH FROZEN PLASMA | E9798 | Yes | Liquid Apheresis CONVALESCENT PLASMA | Liquid Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Irradiated|COVID-19 | PLASMA Conv AFR Liq ACD-A IRD COVID-19 | 120 |
| FRESH FROZEN PLASMA | E9799 | Yes | Liquid CONVALESCENT PLASMA | Liquid CONVALESCENT PLASMA|CPD/XX/refg|Irradiated|COVID-19 | PLASMA Conv Liq CPD IRD COVID-19 | 624 |
| FRESH FROZEN PLASMA | E9800 | Yes | Liquid Apheresis CONVALESCENT PLASMA | Liquid Apheresis CONVALESCENT PLASMA|CPD/XX/refg|Irradiated|COVID-19 | PLASMA Conv AFR Liq CPD IRD COVID-19 | 120 |
| FRESH FROZEN PLASMA | E9801 | Yes | CONVALESCENT PLASMA | CONVALESCENT PLASMA|CPD/XX/<=-18C|Irradiated|COVID-19 | PLASMA Conv CPD IRD COVID-19 | 8760 |
| FRESH FROZEN PLASMA | E9802 | Yes | CONVALESCENT PLASMA | CONVALESCENT PLASMA|CP2D/XX/<=-18C|COVID-19 | PLASMA Conv CP2D COVID-19 | 8760 |
| FRESH FROZEN PLASMA | E9803 | Yes | Thawed CONVALESCENT PLASMA | Thawed CONVALESCENT PLASMA|CP2D/XX/refg|COVID-19 | PLASMA Conv Thaw CP2D COVID-19 | 120 |
| FRESH FROZEN PLASMA | E9804 | Yes | CONVALESCENT PLASMA | CONVALESCENT PLASMA|CPDA-1/XX/<=-18C|COVID-19 | PLASMA Conv CPDA-1 COVID-19 | 8760 |
| FRESH FROZEN PLASMA | E9805 | Yes | CONVALESCENT PLASMA | CONVALESCENT PLASMA|CPDA-1/XX/<=-18C|Psoralen-treated|COVID-19 | PLASMA Conv CPDA-1 Psoraln COVID-19 | 8760 |
| FRESH FROZEN PLASMA | E9806 | Yes | Liquid Apheresis CONVALESCENT PLASMA | Liquid Apheresis CONVALESCENT PLASMA|NS/XX/refg|Irradiated|1st container|COVID-19 | PLASMA Conv AFR Liq NS IRD 1C COVID-19 | 120 |
| FRESH FROZEN PLASMA | E9807 | Yes | Liquid Apheresis CONVALESCENT PLASMA | Liquid Apheresis CONVALESCENT PLASMA|NS/XX/refg|Irradiated|2nd container|COVID-19 | PLASMA Conv AFR Liq NS IRD 2C COVID-19 | 120 |
| FRESH FROZEN PLASMA | E9808 | Yes | Liquid Apheresis CONVALESCENT PLASMA | Liquid Apheresis CONVALESCENT PLASMA|NS/XX/refg|Irradiated|3rd container|COVID-19 | PLASMA Conv AFR Liq NS IRD 3C COVID-19 | 120 |
| FRESH FROZEN PLASMA | E9809 | Yes | Liquid Apheresis CONVALESCENT PLASMA | Liquid Apheresis CONVALESCENT PLASMA|NS/XX/refg|Irradiated|4th container|COVID-19 | PLASMA Conv AFR Liq NS IRD 4C COVID-19 | 120 |
| FRESH FROZEN PLASMA | E9810 | Yes | Liquid CONVALESCENT PLASMA | Liquid CONVALESCENT PLASMA|CPDA-1/XX/refg|COVID-19 | PLASMA Conv Liq CPDA-1 COVID-19 | 624 |
| FRESH FROZEN PLASMA | E9811 | Yes | Thawed CONVALESCENT PLASMA | Thawed CONVALESCENT PLASMA|CPDA-1/XX/refg|COVID-19 | PLASMA Conv Thaw CPDA-1 COVID-19 | 120 |

# Table 3: Possible Modifications for Newly Added Products

| **Modification** | **Method** | **Source Product Code** | **Source Product Name** | **Target Product Code** | **Target Product Name** |
| --- | --- | --- | --- | --- | --- |
| Thaw | CLOSED | E9753 | Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|Irradiated|COVID-19 | E9793 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Irradiated|COVID-19 |
| Thaw | CLOSED | E9771 | Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|Psoralen-treated|COVID-19 | E9788 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Psoralen-treated|COVID-19 |
| Thaw | CLOSED | E9784 | Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|1st container|Psoralen-treated|COVID-19 | E9789 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|1st container|Psoralen-treated|COVID-19 |
| Thaw | CLOSED | E9785 | Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|2nd container|Psoralen-treated|COVID-19 | E9790 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|2nd container|Psoralen-treated|COVID-19 |
| Thaw | CLOSED | E9786 | Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|3rd container|Psoralen-treated|COVID-19 | E9791 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|3rd container|Psoralen-treated|COVID-19 |
| Thaw | CLOSED | E9787 | Apheresis CONVALESCENT PLASMA|ACD-A/XX/<=-18C|4th container|Psoralen-treated|COVID-19 | E9792 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|4th container|Psoralen-treated|COVID-19 |
| Thaw | CLOSED | E9794 | CONVALESCENT PLASMA|CPD/XX/<=-25C|COVID-19 | E9780 | Thawed CONVALESCENT PLASMA|CPD/XX/refg|COVID-19 |
| Thaw | CLOSED | E9795 | Apheresis CONVALESCENT PLASMA|NaCitrate/XX/<=-25C|COVID-19 | E9782 | Thawed Apheresis CONVALESCENT PLASMA|NS/XX/refg|COVID-19 |
| Thaw | CLOSED | E9802 | CONVALESCENT PLASMA|CP2D/XX/<=-18C|COVID-19 | E9803 | Thawed CONVALESCENT PLASMA|CP2D/XX/refg|COVID-19 |
| Thaw | CLOSED | E9804 | CONVALESCENT PLASMA|CPDA-1/XX/<=-18C|COVID-19 | E9811 | Thawed CONVALESCENT PLASMA|CPDA-1/XX/refg|COVID-19 |
| Irradiate | CLOSED | E9738 | Liquid CONVALESCENT PLASMA|CPD/XX/refg|COVID-19 | E9799 | Liquid CONVALESCENT PLASMA|CPD/XX/refg|Irradiated|COVID-19 |
| Irradiate | CLOSED | E9739 | Liquid Apheresis CONVALESCENT PLASMA|CPD/XX/refg|COVID-19 | E9800 | Liquid Apheresis CONVALESCENT PLASMA|CPD/XX/refg|Irradiated|COVID-19 |
| Irradiate | CLOSED | E9750 | Liquid Apheresis CONVALESCENT PLASMA|NS/XX/refg|COVID-19 | E9797 | Liquid Apheresis CONVALESCENT PLASMA|NS/XX/refg|Irradiated|COVID-19 |
| Irradiate | CLOSED | E9751 | Liquid CONVALESCENT PLASMA|NS/XX/refg|COVID-19 | E9796 | Liquid CONVALESCENT PLASMA|NS/XX/refg|Irradiated|COVID-19 |
| Irradiate | CLOSED | E9752 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|COVID-19 | E9793 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Irradiated|COVID-19 |
| Irradiate | CLOSED | E9758 | Liquid Apheresis CONVALESCENT PLASMA|NS/XX/refg|1st container|COVID-19 | E9806 | Liquid Apheresis CONVALESCENT PLASMA|NS/XX/refg|Irradiated|1st container|COVID-19 |
| Irradiate | CLOSED | E9759 | Liquid Apheresis CONVALESCENT PLASMA|NS/XX/refg|2nd container|COVID-19 | E9807 | Liquid Apheresis CONVALESCENT PLASMA|NS/XX/refg|Irradiated|2nd container|COVID-19 |
| Irradiate | CLOSED | E9760 | Liquid Apheresis CONVALESCENT PLASMA|NS/XX/refg|3rd container|COVID-19 | E9808 | Liquid Apheresis CONVALESCENT PLASMA|NS/XX/refg|Irradiated|3rd container|COVID-19 |
| Irradiate | CLOSED | E9761 | Liquid Apheresis CONVALESCENT PLASMA|NS/XX/refg|4th container|COVID-19 | E9809 | Liquid Apheresis CONVALESCENT PLASMA|NS/XX/refg|Irradiated|4th container|COVID-19 |
| Irradiate | CLOSED | E9773 | Liquid Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|COVID-19 | E9798 | Liquid Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Irradiated|COVID-19 |
| Split/Divide | CLOSED | E9788 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Psoralen-treated|COVID-19 | E9788 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Psoralen-treated|COVID-19 |
| Split/Divide | CLOSED | E9789 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|1st container|Psoralen-treated|COVID-19 | E9789 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|1st container|Psoralen-treated|COVID-19 |
| Split/Divide | CLOSED | E9790 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|2nd container|Psoralen-treated|COVID-19 | E9790 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|2nd container|Psoralen-treated|COVID-19 |
| Split/Divide | CLOSED | E9791 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|3rd container|Psoralen-treated|COVID-19 | E9791 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|3rd container|Psoralen-treated|COVID-19 |
| Split/Divide | CLOSED | E9792 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|4th container|Psoralen-treated|COVID-19 | E9792 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|4th container|Psoralen-treated|COVID-19 |
| Split/Divide | CLOSED | E9793 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Irradiated|COVID-19 | E9793 | Thawed Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Irradiated|COVID-19 |
| Split/Divide | CLOSED | E9796 | Liquid CONVALESCENT PLASMA|NS/XX/refg|Irradiated|COVID-19 | E9796 | Liquid CONVALESCENT PLASMA|NS/XX/refg|Irradiated|COVID-19 |
| Split/Divide | CLOSED | E9797 | Liquid Apheresis CONVALESCENT PLASMA|NS/XX/refg|Irradiated|COVID-19 | E9797 | Liquid Apheresis CONVALESCENT PLASMA|NS/XX/refg|Irradiated|COVID-19 |
| Split/Divide | CLOSED | E9798 | Liquid Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Irradiated|COVID-19 | E9798 | Liquid Apheresis CONVALESCENT PLASMA|ACD-A/XX/refg|Irradiated|COVID-19 |
| Split/Divide | CLOSED | E9799 | Liquid CONVALESCENT PLASMA|CPD/XX/refg|Irradiated|COVID-19 | E9799 | Liquid CONVALESCENT PLASMA|CPD/XX/refg|Irradiated|COVID-19 |
| Split/Divide | CLOSED | E9800 | Liquid Apheresis CONVALESCENT PLASMA|CPD/XX/refg|Irradiated|COVID-19 | E9800 | Liquid Apheresis CONVALESCENT PLASMA|CPD/XX/refg|Irradiated|COVID-19 |
| Split/Divide | CLOSED | E9803 | Thawed CONVALESCENT PLASMA|CP2D/XX/refg|COVID-19 | E9803 | Thawed CONVALESCENT PLASMA|CP2D/XX/refg|COVID-19 |
| Split/Divide | CLOSED | E9806 | Liquid Apheresis CONVALESCENT PLASMA|NS/XX/refg|Irradiated|1st container|COVID-19 | E9806 | Liquid Apheresis CONVALESCENT PLASMA|NS/XX/refg|Irradiated|1st container|COVID-19 |
| Split/Divide | CLOSED | E9807 | Liquid Apheresis CONVALESCENT PLASMA|NS/XX/refg|Irradiated|2nd container|COVID-19 | E9807 | Liquid Apheresis CONVALESCENT PLASMA|NS/XX/refg|Irradiated|2nd container|COVID-19 |
| Split/Divide | CLOSED | E9808 | Liquid Apheresis CONVALESCENT PLASMA|NS/XX/refg|Irradiated|3rd container|COVID-19 | E9808 | Liquid Apheresis CONVALESCENT PLASMA|NS/XX/refg|Irradiated|3rd container|COVID-19 |
| Split/Divide | CLOSED | E9809 | Liquid Apheresis CONVALESCENT PLASMA|NS/XX/refg|Irradiated|4th container|COVID-19 | E9809 | Liquid Apheresis CONVALESCENT PLASMA|NS/XX/refg|Irradiated|4th container|COVID-19 |
| Split/Divide | CLOSED | E9810 | Liquid CONVALESCENT PLASMA|CPDA-1/XX/refg|COVID-19 | E9810 | Liquid CONVALESCENT PLASMA|CPDA-1/XX/refg|COVID-19 |
| Split/Divide | CLOSED | E9811 | Thawed CONVALESCENT PLASMA|CPDA-1/XX/refg|COVID-19 | E9811 | Thawed CONVALESCENT PLASMA|CPDA-1/XX/refg|COVID-19 |

This is the last page of *VistA Blood Establishment Computer Software (VBECS) 2.3.2 Rev D Release Notes*.